COSTEM 2024
  • Acute leukemia
  • Antibody-drug conjugates
  • Artificial Intelligence (AI)
  • Bi-specific antibodies
  • CMV infection
  • CAR T-cell therapy and cellular therapy
  • Cord blood transplantation
  • Donor lymphocyte infusion
  • Genome editing and gene therapy
  • GvHD prevention and treatment
  • Haploidentical stem cell transplantation
  • Hodgkin and non-Hodgkin lymphoma
  • Infectious complications
  • Mesenchymal stem cells
  • Multiple myeloma
  • Myeloproliferative neoplasm
  • Myelodysplastic syndrome
  • NK Cell therapy
  • Pediatric indications for transplantation
  • Relapse prevention
  • Stem cell transplantation
  • TCR engineering-based immunotherapy
  • Toxicity post transplantation (VOD, TMA)
  • Transplant for severe aplastic anemia and haemoglobinopathies
  • Virus specific T-cell therapy